China, Nine Other Nations Represented At U.S. FDA Heparin Talks
This article was originally published in PharmAsia News
Executive Summary
China regulators joined counterparts from nine other countries at U.S.-hosted meetings to discuss the status of the blood-thinner heparin. Contaminated supplies of heparin were traced to China after 62 deaths were reported among patients who had been given the heparin drug. Details of the discussions were not revealed in advance of an April 21 meeting orchestrated by the U.S. FDA, which hosted the two days of meetings with the representatives. (Click here for more